Cancer cells can sometimes find a way to survive the very drugs designed to stop them, leaving researchers searching for new ways to fight back. Now, scientists investigating drug-resistant lung cancer have uncovered an unexpected possibility involving mebendazole, a medicine commonly used to treat parasitic worm infections. When researchers combined it with a targeted cancer drug, the treatment reduced the viability of resistant cancer cells in laboratory experiments and slowed tumor growth in mice.
The findings, published in PLOS ONE, could open a new direction for investigating how cancer cells respond when treatment stops working. The researchers tested the combination of mebendazole and gefitinib, a drug that targets a growth-related protein involved in certain lung cancers. Although the results are encouraging, the experiments remain at an early stage, and the combination has not been established as a safe or effective treatment for people. The research instead offers a closer look at how scientists might exploit weaknesses that emerge when cancer cells develop resistance.
Why Drug-Resistant Lung Cancer Is So Difficult to Treat
Targeted cancer medicines work by interfering with specific biological processes that allow cancer cells to grow and multiply. In certain cases of non-small cell lung cancer, genetic changes affect a protein called EGFR, which helps transmit signals that regulate cell growth. When these signals remain active, cancer cells can continue multiplying, making EGFR an important target for treatment.
Gefitinib blocks this growth signaling, but cancer cells can eventually develop resistance that allows them to survive despite the drug. Once that happens, the original treatment may become less effective at controlling the tumor, creating a challenge for researchers and clinicians. Scientists are therefore investigating whether resistant cells develop other vulnerabilities that could be targeted alongside the pathways existing medicines already affect.
The research team focused on a laboratory model of EGFR-mutant non-small cell lung cancer that had become resistant to gefitinib. Their approach was to investigate whether disrupting another essential cellular process could make these resistant cells more vulnerable. Rather than relying on the targeted cancer drug alone, they tested whether a second medicine could place additional stress on the cells and interfere with their ability to keep multiplying.
How a Deworming Medicine Became Part of the Research
Mebendazole is commonly used to treat infections caused by parasitic worms. It works by interfering with microtubules, tiny structures inside cells that help maintain their organization and support important functions. These structures also play a role in cell division, making them relevant to the biological processes that rapidly multiplying cells depend on.
The researchers paired mebendazole with gefitinib because the medicines affect different cellular processes. Gefitinib blocks the signals that encourage cancer cells to grow, while mebendazole interferes with the internal machinery needed for normal cellular functions. The team hypothesized that applying pressure to both processes simultaneously could make it harder for resistant cancer cells to survive.
The combination was designed to increase the demands placed on cells as they attempted to replicate their DNA and divide. DNA replication is essential for cell multiplication, and disruptions during this process can contribute to cellular damage. The researchers investigated whether combining the two medicines could create a greater obstacle for resistant cancer cells than either drug could create on its own.
Laboratory Tests Revealed a Difference Between Treatments
The first stage involved testing the medicines on resistant human lung cancer cells in laboratory conditions. After 72 hours, gefitinib alone left cell viability at approximately 93% of the untreated control level. A low concentration of mebendazole alone reduced the measurement to around 80%, while combining the two medicines brought it down to approximately 38%.
A higher concentration of mebendazole used on its own reduced cell viability further, to around 30%. The combination therefore produced a substantial reduction using a lower concentration of mebendazole than the higher-dose comparison group. These measurements gave the researchers a reason to investigate the combination further, although cell viability in a laboratory experiment cannot predict with certainty how a treatment will perform inside the human body.
The experiments also detected DNA damage in treated cells, including breaks affecting one or both strands of DNA. The researchers interpreted these results as consistent with increased stress associated with DNA replication. However, the precise mechanism remains uncertain, and the study did not directly establish exactly how the DNA-copying machinery failed or formally quantify whether the two drugs produced a synergistic effect.
What Happened When Researchers Tested the Combination in Mice
After the laboratory experiments, the team tested the treatment in mice carrying tumors grown from the resistant human cancer cells. The 40-day experiment included eight mice in each treatment group, allowing researchers to compare tumor growth across untreated animals, animals receiving either drug alone, and animals receiving the combination. The main measurement was the median time required for tumors to double in size.
The untreated group had a median tumor-doubling time of 6.2 days. Mebendazole alone extended that period to 10.3 days, while gefitinib alone increased it to 15.5 days. The combination produced the longest result, with a median tumor-doubling time of 25 days, suggesting that the paired treatment slowed tumor growth more effectively than either medicine alone in this experimental model.
These results are encouraging because they suggest that combining treatments affecting different cellular processes could offer a way to investigate certain forms of drug resistance. However, the tumors were not eliminated, and slower growth does not establish that the treatment would extend survival or improve quality of life in people. The findings also come from one resistant cancer model, so further research is needed to determine whether the same effects occur in other tumors.
The Biggest Questions Scientists Still Need to Answer
One major question is whether mebendazole actually reverses resistance to gefitinib or adds a separate source of cellular damage that makes resistant cells less likely to survive. These possibilities could produce similar experimental observations, but they would have different implications for understanding how the combination works. The researchers have not yet established that the treatment fully restores sensitivity to gefitinib.
Another challenge is determining whether the findings can be reproduced in additional cancer models. Lung cancers can develop resistance through different biological mechanisms, meaning a combination that works against one laboratory model may not work against others. Testing additional resistant cell lines and patient-derived tumor models would help researchers establish whether the observed effect has broader relevance.
The team has also identified resistance to osimertinib, a newer EGFR-targeted cancer treatment, as an important subject for future investigation. Understanding whether the same strategy could affect tumors resistant to other targeted medicines would help clarify how widely the approach might apply. For now, the findings support further experiments rather than conclusions about how patients might respond.
Why Safety and Drug Exposure Remain Major Concerns
Mebendazole already has an established medical use against parasitic worm infections, but its safety and effectiveness in that setting cannot automatically be applied to cancer treatment. The amount of medicine reaching a tumor can influence whether a treatment has an effect, and mebendazole’s absorption after oral administration can vary. Researchers must establish whether effective concentrations could reach human tumors consistently without causing unacceptable harm.
The mouse experiments did not show sustained body-weight loss among treated animals, but that observation alone cannot establish safety. Further work must examine potential effects on organs and healthy tissues, the consequences of prolonged exposure, and possible interactions between the medicines. These questions are particularly important when combining drugs that affect different processes inside cells.
Before the treatment could be considered for clinical use, researchers would need stronger evidence from additional preclinical experiments and careful assessments of exposure and safety. The results also do not justify taking mebendazole independently or combining it with prescribed cancer medicines. Anyone receiving cancer treatment should discuss medication changes with their oncology team rather than attempting an unproven combination.
What the Findings Could Mean for Future Cancer Research
The study offers an example of how scientists are investigating weaknesses that may emerge when cancer cells adapt to treatment. By combining a targeted drug with a medicine that interferes with another cellular process, researchers observed lower cancer-cell viability and slower tumor growth in their experimental models. The results provide a potential direction for future research into certain forms of drug resistance.
Much remains unknown, including whether the approach can be reproduced across different tumors, whether the drugs can reach effective concentrations safely, and whether the combination would benefit patients. Those questions must be answered before its clinical potential can be assessed. The study does not establish a new lung cancer treatment, but it gives researchers a specific strategy to test more rigorously.
The next step is to determine whether the weakness observed in resistant cancer cells can be reproduced reliably and targeted without unacceptable damage to healthy tissue. That evidence will determine whether this unexpected pairing remains a laboratory finding or develops into a treatment strategy worth testing in people.
